Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CERo Therapeutics HoldingsCERO -12.75% Shareholder Yield % is 129.72% as of Mar. 2026, which is 1796% above its 10-year median of 6.84. The stock has 2 warning signs investors should review. Among 1,297 Biotechnology companies, CERo Therapeutics Holdings ranks better than 99.38% on this metric.
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. It is a measure of shareholder return.
As of today, CERo Therapeutics Holdings's Shareholder Yield % was 129.72%.
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. The term was coined by William W. Priest of Epoch Investment Partners in a paper in 2005 entitled The Case for Shareholder Yield as a Dominant Driver of Future Equity Returns. William Priest indicated that "shareholder yield is a term that we came up with to reflect the various ways dividends can be paid to owners of a business in a publicly-traded company."
Dividend Yield % shows how much a company pays out in dividends each year relative to its stock price, which is most obvious form of shareholder return.
Buyback Yield % is the net repurchase of shares outstanding over the market capital of the company. Shares repurchases also increase shareholder value by returning the money back to shareholders.
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced.
CERo Therapeutics Holdings Shareholder Yield % Related Terms
CERo Therapeutics Holdings Shareholder Yield % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CERO vs WINT, LIPO, RMTG: Shareholder Yield % Comparison
For the Biotechnology subindustry, CERo Therapeutics Holdings's Shareholder Yield %, along with its competitors' market caps and Shareholder Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CERo Therapeutics Holdings Shareholder Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CERo Therapeutics Holdings's Shareholder Yield % distribution charts can be found below:
* The bar in red indicates where CERo Therapeutics Holdings's Shareholder Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Shareholder Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
CERo Therapeutics Holdings (CERO) has a Shareholder Yield % of 129.72% as of Mar. 2026. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on CERo Therapeutics Holdings and its competitors. This is 1796% above median its historical median of 6.84. Over the past decade, CERo Therapeutics Holdings' Shareholder Yield % has ranged from 4.14 to 129.72. According to the industry distribution chart, CERo Therapeutics Holdings ranks #8 out of 1297 companies in the Biotechnology industry, placing it in the top 0.59999999999999%.
Is CERo Therapeutics Holdings' Shareholder Yield % too high?
CERo Therapeutics Holdings' current Shareholder Yield % of 129.72% is 1796% above median its 10-year median of 6.84. Over the past 10 years, this metric has ranged from a low of 4.14 to a high of 129.72. Based on the distribution chart, CERo Therapeutics Holdings ranks #8 out of 1297 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does CERo Therapeutics Holdings' Shareholder Yield % compare to WINT and LIPO?
According to the Biotechnology industry distribution chart, CERo Therapeutics Holdings ranks #8 out of 1297 companies for Shareholder Yield %. This places CERo Therapeutics Holdings in the top 1% of its industry — outperforming the majority of peers. Historically, CERo Therapeutics Holdings' own Shareholder Yield % has ranged from 4.14 to 129.72 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shareholder Yield % for a Biotechnology company?
A good Shareholder Yield % depends on the Biotechnology industry context. However, Shareholder Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shareholder Yield % mean?
A high Shareholder Yield % can signal that a stock is expensive relative to its fundamentals. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on CERo Therapeutics Holdings and its competitors. CERo Therapeutics Holdings's current Shareholder Yield % is 129.72%, which is 1796% above median its own 10-year median of 6.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CERo Therapeutics Holdings stock overvalued right now?
CERo Therapeutics Holdings (CERO) has a current Shareholder Yield % of 129.72%. The current Shareholder Yield % is 129.72%, which is 1796% above median its 10-year median of 6.84. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shareholder Yield % calculated?
Shareholder Yield % is calculated from a company's financial statements. For CERo Therapeutics Holdings (CERO), the current Shareholder Yield % is 129.72% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CERo Therapeutics Holdings Inc is an immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. The company's molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CERO has been successfully added to your 
